October 24th 2020
By Deana Ferreri, PhD
European investigators have derived a set of core principals for developing higher utilization of biosimilars.
October 14th 2020
By Tony Hagen
Amgen's 2020 biosimilar report goes into detail on market share and costs for biosimilars across the therapeutic spectrum in the United States.
Alexion and Celltrion separately announce advances in their drug development and marketing efforts.
October 12th 2020
By Skylar Jeremias
Sometimes the reference product exhibits pricing resistance against the competitive effect of biosimilars, according to a Pharmaceutical Strategies Group report.
September 29th 2020
California has become the first state to implement a policy to produce and distribute its own drug products to help lower costs.
September 26th 2020
An advance is notched for the ravulizumab (Ultomiris) follow-on product from Alexion. Clinical findings in atypical hemolytic uremic syndrome (aHUS) are provided.
September 25th 2020
A diverse panel from practice, payer, and wholesale perspectives convened at The American Journal of Managed Care®'s Patient-Centered Oncology Care® 2020 virtual conference to hash out one of the hottest issues in biosimilar availability right now.
September 22nd 2020
The Committee for Medicinal Products for Human Use (CHMP) recommendation for ravulizumab (Ultomiris) is for a dosage that involves a less rigorous schedule for administration.
September 21st 2020
Lotus and CKD Pharmaceutical intend to be among the first to bring a darbepoetin alpha biosimilar to Southeast Asia.
August 22nd 2020
Intract Pharma believes infliximab can be delivered orally and, in conjunction with Celltrion Group, aims to apply its technology and expertise to make it happen.
